Ultragenyx prelim 2025 revenue $672-674M beats guidance; cash $735M; two gene therapy approvals possible in 2026

Ultragenyx Pharmaceutical Inc.

2025-FY EPS reported -$5.83 revenue$673,000,000

Preliminary FY2025 total revenue $672-674M, ~20% YoY, exceeding top end of guidance.
Crysvita revenue $480-482M (17% YoY, above guidance); Dojolvi $95-97M (9% YoY, at guidance midpoint).
Cash and investments ~$735M at year-end 2025; full Q4/FY results and 2026 guidance due Feb 2026.
2026 catalysts: DTX401 (GSDIa) PDUFA Q3; UX111 (MPS IIIA) BLA resubmission early 2026; GTX-102 (Angelman) Phase 3 data H2 2026.
UX701 (Wilson disease) pivotal data H1 2026; UX143 (osteogenesis imperfecta) data presented at JPM conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.